Legend and Novartis sign $100M deal for next CAR-T bets

Legend Biotech, which came to the fore in cell therapy when Johnson & Johnson took a major bet in 2017 on what would become Carvykti, has found another Big Pharma partner for its CAR-T pipeline. It’s going with Novartis, the maker of the first FDA-approved CAR-T.

Novartis Click here to view original post